Reports Q4 revenue $16.361M, consensus $7.71M. “We made significant progress advancing the clinical development of Emi-Le in 2024,” said Martin ...

Announced positive initial Phase 1 clinical data and an additional Fast Track designation for Emi-LeInitiated first expansion ...

Personalis, Inc. (Nasdaq: PSNL), in collaboration with Professor Nick Turner, Dr. Isaac Garcia-Murillas and their colleagues at The Institute of Cance ...

Cambridge: AstraZeneca and Daiichi Sankyo's Enhertu (trastuzumab deruxtecan) has been recommended for approval in the ...

Camizestrant with a CDK 4/6 inhibitor had a statistically significant and clinically meaningful improvement in PFS in ...

Gene Hackman and his wife Betsy Arakawa tested negative for carbon monoxide in the initial results of the toxicology report, ...

The two apparently were dead for days or even a couple of weeks when investigators found their bodies Wednesday.

Approval would expand the use of Enhertu to breast cancer patients with nearly undetectable HER2 levels in their tumors.

The peritoneal cavity, which contains the abdominal organs, is a less common but still potential site for breast cancer to ...

Reports Q4 revenue $59.1M, two estimates $52.5M. “We are very pleased with our financial results for the fourth quarter of 2024, as well as for ...

PYX-201 has gained FDA fast track designation in recurrent or metastatic head and neck squamous cell carcinoma.

Metronomic capecitabine plus an aromatase inhibitor improved survival outcomes in hormone receptor-positive, HER2-negative ...